MedTrace Logo

Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma

NCT02732665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-04-05

No results posted yet for this study

Summary

In this study, glycosaminoglycan (GAG) profiling in subjects diagnosed with metastatic renal cell carcinoma (mRCC) is hypothesized to be useful in monitoring drug response and predict radiological response. To this end, glycosaminoglycan scores based on longitudinal samples of plasma and urine in prospectively enrolled patients will be correlated to radiological response to first-line therapy based on current standard-of-care. A positive correlation indicates that glycosaminoglycan scores can successfully detect patients that are not responding to treatment before the scheduled follow-up in which radiological imaging is performed. Data on the extent of metastasis (number of metastatic sites) will be collected to assess whether glycosaminoglycans correlate accordingly.

Conditions

  • Carcinoma, Renal Cell

Sponsors & Collaborators

  • Sahlgrenska University Hospital

    collaborator OTHER

  • University of Modena and Reggio Emilia

    collaborator OTHER

  • Jens Nielsen

    lead OTHER

Principal Investigators

  • Jens Nielsen, PhD · Chalmers University of Technology

  • Ulrika Stierner, M.D. PhD · Sahlgrenska University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-12-31
Completion
2021-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02732665 on ClinicalTrials.gov